Physician profile
Brian James King
NPI 1407274756
$1,964.58
in general payments reported to CMS, 2019-2025
22 companies · $207 in 2025
The $207 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $15.47 · 2021: $166 · 2022: $313 · 2023: $361 · 2024: $601 · 2025: $207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,168.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $325.82 | 2023-2025 | |
| Organogenesis INC. | $212.31 | 2024-2025 | Puraply Wound Matrix, Via Matrix |
| Novartis Pharmaceuticals Corporation | $176.69 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $157.89 | 2019-2021 | |
| Bioventus LLC | $148.87 | 2022 | |
| Kerecis Limited | $148.08 | 2022-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Verrica Pharmaceuticals INC. | $139.87 | 2023-2024 | Ycanth |
| Genzyme Corporation | $121.38 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $100.86 | 2021-2023 | Dupixent, Libtayo |
| Allergan, INC. | $98.76 | 2020-2022 | |
| Sun Pharmaceutical Industries INC. | $44.94 | 2023-2025 | Ilumya |
| Leo Pharma INC. | $44.30 | 2022-2023 | Adbry |
| Arcutis Biotherapeutics, INC. | $36.54 | 2024-2025 | Zoryve |
| Amgen INC. | $34.58 | 2022-2024 | Otezla |
| Pfizer INC. | $31.09 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $26.76 | 2024 | Grafix Xc |
| Janssen Biotech, INC. | $24.14 | 2024 | Tremfya |
| Integra Lifesciences Corporation | $20.51 | 2023 | Integra, Integra Dermal Regeneration Template, Primatrix |
| Dermavant Sciences, INC. | $18.56 | 2023 | Vtama |
| Zyla Life Sciences, INC. | $17.78 | 2019 | |
| Genentech USA, INC. | $17.58 | 2019 | |
| Galderma Laboratories, L.P. | $17.27 | 2025 | Nemluvio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.